Novocure announces results from Phase 3 PANOVA-3 trial

Novocure (NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy for pancreatic cancer will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with compared to those who received gemcitabine and nab-paclitaxel alone. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death.